In the previous issue of Critical Care, Kumaraswamy and colleagues [1] show that plasma apolipoprotein M (apoM) is reduced in patients with sepsis and systemic infl am matory response syndrome (SIRS). Patients with severe sepsis and SIRS had the most pronounced drop compared to the control group. Th is suggests that apoM is a negative acute phase reactant. Th is is the fi rst report of such a dramatic decrease in plasma apoM in a group of patients without genetic diseases aff ecting high-density lipo protein metabolism but solely based on clinical scores for sepsis. Th is indicates the potential importance of the present study [1] . Interestingly, plasma apoM is decreased by 9% in patients with type II diabetes compared to controls [2] . Type II diabetes is also associated with low grade infl ammation, and therefore this could support the idea of apoM being a new marker of infl ammatory diseases.
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ApoM is an apolipoprotein mainly bound to highdensity lipoprotein (HDL) particles [3] ; however, plasma apoM is not only associated with HDL cholesterol but also with low-density lipo protein cholesterol in normal individuals [4] . Sepsis decreases HDL cholesterol and several HDL apolipo proteins, which may aff ect the clinical course in sepsis. For instance, both apoCI and apoAI are low in sepsis patients and are able to bind and initiate elimination of lipopolysaccharide (LPS) from plasma [5, 6] . Binding of LPS to the HDL particles is thought to be part of the innate immune response. Sepsis also increases apoE-enriched HDL particles; however, apoE has both been shown to protect against LPSinduced sepsis by binding LPS [7] , but also to accelerate cytokine production and increase mortality in animal models [8] . ApoL, another apolipoprotein on HDL particles having anti-trypanolytic eff ects, also plays an important role in the innate immune system [9] . Th e present study by Kumaraswamy and colleagues [1] adds apoM to the list of apolipoproteins on HDL particles that are aff ected by sepsis. As such, apoM might have potential as a marker of severe disease, but recent knowledge on apoM biology could also indicate a possible eff ect on the clinical course of sepsis.
Leaking vessels are a feature of severe sepsis and SIRS, causing increased distribution volume and shock. Sphingosine-1-P (S1P) preserves endothelial function, induces formation of tight junctions, and prevents vascular leak. S1P is a small bioactive lipid, carried by apoM in the HDL particle, and studies of apoM-defi cient mice suggest that the apoM-S1P complex is crucial for maintaining normal endothelial function and vascular permeability [10] . Plasma apoM and S1P correlate positively, suggesting that sepsis patients could have decreased plasma levels of S1P as a consequence of low apoM levels; however, no reports on plasma levels of S1P in sepsis patients have so far been published. Genetically modifi ed mice with low plasma S1P levels are more prone to LPS infections and develop more severe lung symptoms than wild-type mice [11, 12] . Th e drug FTY720
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is an analog of S1P that interacts with the S1P1 receptor, and reduces attack frequency in patients with multiple sclerosis [13] . FTY720 and new S1P agonists might have benefi cial eff ects in diseases involving, for example, leaky endothelial barrier and enhanced migration of infl ammatory cells, such as sepsis. Indeed, when mice or rabbits are treated with LPS, the vascular leak and infl ammatory response can be dampened by treatment with FTY720 or S1P [14, 15] . Also, mice infected with H1N1 infl uenza die due to a 'cytokine storm' , but treatment of mice with an S1P1 receptor agonist prevents this lethal eff ect, implying that S1P and its receptors have important functions in cytokine amplifi cation [16] . A future possibility could therefore be to explore the protective role of both plasma apoM and plasma S1P and further investigate the use of S1P analogs to improve vascular barrier function in sepsis patients and as modulators of the infl ammatory response.
